BR112012016809A2 - método e composições para a aplicação de moxifloxacina ao ouvido - Google Patents

método e composições para a aplicação de moxifloxacina ao ouvido

Info

Publication number
BR112012016809A2
BR112012016809A2 BR112012016809A BR112012016809A BR112012016809A2 BR 112012016809 A2 BR112012016809 A2 BR 112012016809A2 BR 112012016809 A BR112012016809 A BR 112012016809A BR 112012016809 A BR112012016809 A BR 112012016809A BR 112012016809 A2 BR112012016809 A2 BR 112012016809A2
Authority
BR
Brazil
Prior art keywords
ear
moxifloxacin
compositions
tympanic membrane
applying
Prior art date
Application number
BR112012016809A
Other languages
English (en)
Inventor
W Y Cheung Belinda
Michael Wall G
J Sawchuk Ronald
Original Assignee
Novartis Ag
Univ Minnesota
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44306169&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR112012016809(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag, Univ Minnesota filed Critical Novartis Ag
Publication of BR112012016809A2 publication Critical patent/BR112012016809A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0046—Ear
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Inorganic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Saccharide Compounds (AREA)

Abstract

patente de invenção: métodos e composições para a aplicação de moxifloxacina ao ouvido. são descritos métodos e materiais úteis para a aplicação de moxifloxacina o ouvido. os métodos envolvem o fornecimento que contém pelo menos um agente viscogênico e moxifloxacina ou um seu sal à superfície epidérmica da membrana timpânica via o canal do ouvido. a composição é derivada à membrana timpânica em uma forma escoável e, depois do fornecimento à membrana timpânica, se torna suficientemente viscosa tal que a moxifloxacina está localizada contra a membrana timpânica. tais composições podem ser usadas para profilaticamente e/ou terapeuticamente tratar condições do ouvido interno e médio, incluindo otite média.
BR112012016809A 2010-01-07 2011-01-07 método e composições para a aplicação de moxifloxacina ao ouvido BR112012016809A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US29301910P 2010-01-07 2010-01-07
PCT/US2011/020531 WO2011085209A2 (en) 2010-01-07 2011-01-07 Methods and compositions for applying moxifloxacin to the ear

Publications (1)

Publication Number Publication Date
BR112012016809A2 true BR112012016809A2 (pt) 2017-09-26

Family

ID=44306169

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112012016809A BR112012016809A2 (pt) 2010-01-07 2011-01-07 método e composições para a aplicação de moxifloxacina ao ouvido

Country Status (23)

Country Link
US (1) US20120289541A1 (pt)
EP (2) EP2521547B1 (pt)
JP (3) JP2013516485A (pt)
KR (2) KR20180027611A (pt)
CN (2) CN102791270A (pt)
AU (1) AU2011204275B2 (pt)
BR (1) BR112012016809A2 (pt)
CA (1) CA2786525A1 (pt)
CL (1) CL2012001835A1 (pt)
CY (1) CY1119493T1 (pt)
DK (1) DK2521547T3 (pt)
ES (1) ES2644826T3 (pt)
HR (1) HRP20171592T1 (pt)
HU (1) HUE035586T2 (pt)
LT (1) LT2521547T (pt)
MX (1) MX337419B (pt)
NO (1) NO2521547T3 (pt)
PL (1) PL2521547T3 (pt)
PT (1) PT2521547T (pt)
RU (2) RU2016101214A (pt)
SI (1) SI2521547T1 (pt)
WO (1) WO2011085209A2 (pt)
ZA (1) ZA201205965B (pt)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7220431B2 (en) 2002-11-27 2007-05-22 Regents Of The University Of Minnesota Methods and compositions for applying pharmacologic agents to the ear
JP6456285B2 (ja) * 2012-06-28 2019-01-23 ジ アドミニストレイターズ オブ ザ チューレン エデュケイショナル ファンド 選択的重合性組成物およびｉｎｖｉｖｏでのその使用方法
CN103869033B (zh) * 2012-12-14 2016-10-05 南京长澳医药科技有限公司 一种液相色谱法分离测定盐酸莫西沙星及其杂质的方法
JP6255134B1 (ja) * 2016-11-02 2017-12-27 ヴェローチェ・バイオファーマ・エルエルシー 耳炎の治療のための組成物および方法
WO2019113425A1 (en) * 2017-12-08 2019-06-13 The Johns Hopkins University Hypotonic hydrogel formulations for enhanced transport of active agents at mucosal surfaces
CN108593696B (zh) * 2018-04-26 2020-11-03 南京明捷生物医药检测有限公司 一种利用定量核磁测定多肽中三氟乙酸残留的方法
CN117045593B (zh) * 2023-09-19 2024-05-28 上海市第六人民医院 一种用于慢性中耳炎治疗的抗菌温敏水凝胶及其制备方法和应用

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6201072B1 (en) 1997-10-03 2001-03-13 Macromed, Inc. Biodegradable low molecular weight triblock poly(lactide-co- glycolide) polyethylene glycol copolymers having reverse thermal gelation properties
AR020661A1 (es) * 1998-09-30 2002-05-22 Alcon Lab Inc Una composicion farmaceutica topica oftalmica, otica o nasal y el uso de la misma para la manufactura de un medicamento
US6740664B2 (en) * 1998-09-30 2004-05-25 Alcon, Inc. Methods for treating otic and ophthalmic infections
JP3450805B2 (ja) * 2000-08-08 2003-09-29 わかもと製薬株式会社 水性医薬組成物
US7220431B2 (en) * 2002-11-27 2007-05-22 Regents Of The University Of Minnesota Methods and compositions for applying pharmacologic agents to the ear
CA2587081A1 (en) * 2004-12-10 2006-06-22 Alcon, Inc. Compositions for treatment of ear infections
US8822410B2 (en) * 2008-05-19 2014-09-02 Children's Medical Center Corporation Tympanic membrane permeating ear drops and uses thereof

Also Published As

Publication number Publication date
WO2011085209A3 (en) 2011-11-17
PL2521547T3 (pl) 2018-01-31
KR20120114344A (ko) 2012-10-16
LT2521547T (lt) 2017-12-11
EP3305280A1 (en) 2018-04-11
CN102791270A (zh) 2012-11-21
NO2521547T3 (pt) 2018-01-13
PT2521547T (pt) 2017-11-17
MX337419B (es) 2016-03-03
EP2521547B1 (en) 2017-08-16
WO2011085209A2 (en) 2011-07-14
MX2012007928A (es) 2012-11-22
RU2012133568A (ru) 2014-02-20
AU2011204275A1 (en) 2012-08-23
CA2786525A1 (en) 2011-07-14
JP2018076352A (ja) 2018-05-17
ZA201205965B (en) 2014-01-29
ES2644826T3 (es) 2017-11-30
RU2016101214A (ru) 2018-11-21
CN106309356A (zh) 2017-01-11
RU2576029C2 (ru) 2016-02-27
HRP20171592T1 (hr) 2018-02-09
EP2521547A2 (en) 2012-11-14
CY1119493T1 (el) 2018-03-07
KR101835895B1 (ko) 2018-03-07
EP2521547A4 (en) 2014-03-26
KR20180027611A (ko) 2018-03-14
JP2016155808A (ja) 2016-09-01
HUE035586T2 (en) 2018-05-28
CL2012001835A1 (es) 2013-03-22
US20120289541A1 (en) 2012-11-15
DK2521547T3 (da) 2017-11-20
JP2013516485A (ja) 2013-05-13
SI2521547T1 (en) 2018-02-28
AU2011204275B2 (en) 2015-04-02
JP6267246B2 (ja) 2018-01-24

Similar Documents

Publication Publication Date Title
BR112012016809A2 (pt) método e composições para a aplicação de moxifloxacina ao ouvido
CR20200064A (es) Carboxamidas como moduladores de los canales de sodio
AU2016278853A8 (en) Petrolatum-based compositions comprising cationic biocides
BR122021018243A8 (pt) Composição tópica de baixo ph e método para aumentar a aplicação tópica de um ingrediente ativo cosmeticamente aceitável
BR112017012327A8 (pt) benzamidas substituídas por 1,3-tiazol-2-il.
WO2008089151A3 (en) High dose film compositions and methods of preparation
MY160703A (en) Crystalline forms of (r) -5- [3-chloro-4-(2,3-dihydroxy) - benz [z] ylidene] -2- ([z]-propylimino) -3-0-tolyl-thiazolidin-4-one
MX2010014041A (es) Una forma cristalina de posaconazol.
BR112014006220A2 (pt) composições de galacto-ramnogalacturonato para o tratamento de esteatohepatite não alcoólica e de doença de gordura no fígado não alcoólica
BR112012029754A2 (pt) processo cosmético para maquiagem e/ ou cuidado para a pele e/ ou os lábios
MA38399A1 (fr) Formulation sous forme de comprimé, utile pour traiter l'insuffisance cardiaque aiguë et l'insuffisance cardiaque chronique
WO2015157559A3 (en) 10',11'-modified saxitoxins useful for the treatment of pain
GB2541835A (en) Multivesicular liposome formulations of tranexamic acid
NZ596138A (en) Stable topical compositions for 1,2,4-thiadiazole derivatives
MY181928A (en) Sodium channel modulators for the treatment of pain and diabetes
MX340985B (es) Compuestos de n-heteroarilo.
BR112015032326A2 (pt) composições de fibra inorgânicas
WO2014153009A3 (en) Thiosaccharide mucolytic agents
AU2013408771A8 (en) Prebiotic oral care compositions containing an alkyl glycoside
WO2016177908A3 (fr) Procede de traitement des matieres keratiniques a partir de derives de c-glycosides amides, acides ou ester, et la composition cosmetique les contenant
CL2018000430A1 (es) Compuesto de hidroxitriazina y uso médico relacionado.
BR122020011180B8 (pt) formulações injetáveis de compostos de tetraciclina
BR112014026184A2 (pt) composições parasiticídicas compreendendo derivados de benzimidazol, métodos e seus usos
EA201071369A1 (ru) Композиции для лечения выпадения волос
CL2013000542A1 (es) Compuestos derivados de 2-oxo- y 2-tioxo-dihidroquinolina-3-carboxamidas sustituidos, moduladores kcnq2/3; composicion farmaceutica; y su uso para el tratamiento o profilaxis del dolor, de preferencia dolor agudo, dolor cronico, dolor neuropatico, dolor visceral. epilepsia, migraña, entre otros.

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL

B350 Update of information on the portal [chapter 15.35 patent gazette]